J&J’s Sjögren’s disease drug shows promise in Phase 2, boosts prospects of FcRn assets in the autoimmune disease
Johnson & Johnson detailed positive data from a mid-stage trial in people with Sjögren’s disease that, according to some analysts, could be an encouraging signal …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
